New eczema drug shows promise in large chinese trial

NCT ID NCT06173284

First seen Nov 20, 2025 · Last updated May 11, 2026 · Updated 26 times

Summary

This study tested a new medicine called 611 in 519 Chinese adults with moderate-to-severe atopic dermatitis (eczema). The drug works by blocking a protein involved in inflammation. Participants received either 611 or a placebo, and researchers measured how much their skin improved after 16 weeks. The goal was to see if 611 could safely reduce eczema severity and itching.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310003, China

  • Dermatology Hospital of Jiangxi Province

    Nanchang, Jiangxi, 330200, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, 100044, China

  • The Fourth Affiliated Hospital Zhejiang University School of Medicine

    Jinhua, Zhejiang, 322000, China

Conditions

Explore the condition pages connected to this study.